IPCA Laboratories Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 14 Aug 2026

Company page: IPCA Laboratories share price, financials & guidance record

Ipca Laboratories delivered a strong Q1 FY27, marked by robust revenue growth and significant margin expansion, driven by strong export and institutional generic performance. The company raised its full-year revenue and EBITDA margin guidance. While facing challenges from material and logistics costs, and the underperformance of Lyka Labs, Ipca is strategically investing in biotech and capacity expansion, with biosimilar revenues anticipated by FY29-FY30.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 20.7%, net profit up 82.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	2,355	2,245	2,247	2,309	2,556 +9%	2,392 +7%	2,388 +6%	2,788 +21%
Expenses	1,913	1,782	1,818	1,892	2,012	1,859	1,905	2,119
EBITDA	441	463	429	416	545 +24%	533 +15%	484 +13%	670 +61%
Margin	19%	21%	19%	18%	21%	22%	20%	24%
Other income	26	20	-179	33	-30	38	48	25
Interest	23	17	22	19	20	18	20	12
Depreciation	100	98	100	100	103	108	107	111
Profit before tax	345	368	128	331	392 +14%	446 +21%	404 +216%	572 +73%
Tax rate	29%	25%	49%	29%	28%	18%	24%	26%
Net profit	246	276	64	233	281 +14%	364 +32%	307 +380%	424 +82%
EPS	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls